<DOC>
	<DOCNO>NCT02061800</DOCNO>
	<brief_summary>This study research study involve subject diagnose malignant disease , either fail standard therapy unlikely cured standard non-transplant therapy , receive peripheral blood stem cell transplant . A malignant disease include follow : Chronic Myeloid Leukemia ( CML ) chronic phase , accelerate phase blast crisis ; Acute Myelogenous Leukemia ( AML ) ; Myelodysplastic Syndrome ( MDS ) ; Juvenile Myelomonocytic Leukemia ( JMML ) ; Acute Lymphoblastic Leukemia ( ALL ) ; Lymphoma ( Hodgkin 's Non-Hodgkin 's ) The purpose study learn effect CD34+ stem cell selection graft versus host disease ( GVHD ) child , adolescent young adult . CD34+ stem cell cell make type blood cell body . GVHD condition result reaction transplant donor T-lymphocytes ( kind white blood cell ) recipient 's body organ . Study subject offer treatment involve use Miltenyi CliniMacs CD34+ selection device remove T-cells peripheral blood stem cell transplant order decrease risk acute chronic GVHD .</brief_summary>
	<brief_title>CD34+ ( Malignant ) Stem Cell Selection Patients Receiving Allogenic Stem Cell Transplant</brief_title>
	<detailed_description>CD34+ stem cell ( cell make type blood cell body ) select ( remove ) donor 's peripheral blood stem cell . In , T-cells ( type blood cell ) also remove . T-cells cell responsible severe acute chronic graft versus host disease ( GVHD ) . GVHD condition result reaction transplant donor T-lymphocytes ( kind white blood cell ) body organ . There two form : acute ( early ) chronic ( late ) . Acute GVHD may produce skin rash , liver disease , diarrhea , increase risk infection . Chronic GVHD also appear subject without prior acute GVHD . Chronic GVHD may also produce skin rash , liver disease , diarrhea increase risk infection . Chronic GVHD may mild respond agent suppress immune system , could severe . It may also last year . Once CD34 selection process complete , CD34+ stem cell AlloSCT give recipient without T-cells see therapy lessen incidence seriousness graft versus host disease ( GVHD ) . CD34+ stem cell selection AlloSCT study adult malignant non-malignant disease successful engraftment show improvement GVHD . We know CD34+ stem cell selection work prevent severe GVHD child , adolescent young adult . Subjects offer experimental treatment involve use Miltenyi CliniMacs CD34+ selection device remove T-cells peripheral blood stem cell transplant order decrease risk acute chronic GVHD . There 25 subject participate study Columbia University Medical Center . The purpose study learn effect CD34+ stem cell selection GVHD child , adolescent young adult . The goal study : - To determine often acute GVHD occur severe acute GVHD child , adolescent young adult receive CD34+ selection peripheral blood stem cell transplant family member adult unrelated donor . - To determine often primary graft failure secondary graft failure occur child , adolescent young adult receive peripheral blood stem cell transplant family member adult unrelated donor . - To see quickly neutrophil ( infection fight white blood cell ) recover follow CD34+ selection peripheral blood stem cell transplant family member adult unrelated donor . - To see time immune system ( body 's defense system ) recover benefit receive CD34+ selection peripheral blood stem cell transplant family member adult unrelated donor . - To see often bacterial , viral , fungal atypical mycobacteria ( TB-like ) infection occur child , adolescent young adult receive CD34+ selection peripheral blood stem cell transplant family member adult unrelated donor . Study specific requirement occur 2 year post-transplant , although study team collect data progress subject yearly termination study observe subject respond therapy worsen GVHD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>General Eligibility ( All Patients ) Must &lt; 22 year age Diagnosed malignant disease Must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) , must sign informed consent For unrelated donor : A human leukocyte antigen ( HLA ) 8/10 , 9/10 10/10 match unrelated adult donor ( MUD ) require study entry For related donor : A 5/10 , 6/10 , 7/10 , 8/10 , 9/10 10/10 match ( partially match ) family donor require study entry Adequate renal function Adequate liver function Adequate cardiac function Adequate pulmonary function Patients document uncontrolled infection time study entry eligible Females pregnant breast feeding time study entry eligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Unrelated donor transplant</keyword>
	<keyword>Allogenic Stem Cell Transplant</keyword>
	<keyword>Adult Bone Marrow Transplant</keyword>
	<keyword>Pediatric Bone Marrow Transplant</keyword>
	<keyword>Related donor transplant</keyword>
	<keyword>Haploidentical donor transplant</keyword>
	<keyword>Peripheral blood stem cell transplantation</keyword>
	<keyword>Non-malignant disease</keyword>
	<keyword>Malignant disease</keyword>
	<keyword>Bone marrow failure syndrome</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Severe Congenital Neutropenia</keyword>
	<keyword>Amegakaryocytic Thrombocytopenia</keyword>
	<keyword>Diamond-Blackfan Anemia</keyword>
	<keyword>Schwachman Diamond Syndrome</keyword>
	<keyword>Primary Immunodeficiency Syndrome</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Histiocytic Syndrome</keyword>
	<keyword>Familial Hemophagocytic Lymphocytosis</keyword>
	<keyword>Lymphohistiocytosis</keyword>
	<keyword>Macrophage Activation Syndrome</keyword>
	<keyword>Langerhans Cell Histiocytosis ( LCH )</keyword>
	<keyword>Hemoglobinopathies</keyword>
	<keyword>Reduced-Intensity Conditioning</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Cell-beta-thalassemia</keyword>
</DOC>